Please login to the form below

Not currently logged in
Email:
Password:

Piramal pays $635m for US data firm

Decision Resources Group purchase reflects increasing demand for drug market information

Piramal Healthcare, the India-based pharma commpany, is to acquire US healthcare research firm Decision Resources Group for $635m.

The purchase reflects Piramal's increasing ambition in the current uncertain climate to focus its drug discovery efforts based on the best available data.

“The global healthcare industry is facing several challenges, including rising research costs, lower drug approval rates, mounting regulatory pressures and increasingly complex reimbursement models,” said Piramal's chair Ajay Piramal.

“The need for specialist information is critical and the demand is growing.”

The acquisition will see Piramal take control of a company with nearly 300 analysts and projected revenues of $160m during 2012 for services such as web-enabled research, predictive analytics and consulting.

Decision Resources' work covers three segments of the pharma industry: analysis of drug utilisation and therapeutic areas to influence research efforts; support for market access, and the medical technology business.

The deal comes two years after Piramal sold its healthcare solutions business to Abbott Laboratories for $3.8bn, since when PIramal has said it “embarked on a strategy to acquire global growth businesses with sustainable returns”.

Decision Resources will remain as a standalone business headquartered in Burlington, Massachusetts, with the transaction expected to be completed by June 30, 2012.

Its current CEO Peter Hoenigsberg, who will continue to lead the company, emphasised the opportunities for Decision Resources to grow in regions it has limited operations in.

“My team and I are excited to be part of the Piramal Group and are confident that its expertise in acquiring, integrating and growing businesses will support our continued growth,” he said.

“Our customers have indicated that independent, objective, indispensable information from emerging markets is one of their greatest needs and Piramal's experience in emerging markets is important since these markets are the primary avenues for growth in the pharma industry.”

17th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....